Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

[RABBIT-SpA: a new disease register for axial spondyloarthritis and psoriatic arthritis].

Regierer AC, Weiß A, Baraliakos X, Zink A, Listing J, Strangfeld A.

Z Rheumatol. 2019 Mar 12. doi: 10.1007/s00393-019-0613-z. [Epub ahead of print] German.

PMID:
30874933
2.

Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care.

Poddubnyy D, Callhoff J, Spiller I, Listing J, Braun J, Sieper J, Rudwaleit M.

RMD Open. 2018 Dec 5;4(2):e000825. doi: 10.1136/rmdopen-2018-000825. eCollection 2018.

3.

Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Long-Term Anti-Tumor Necrosis Factor Treatment: Six-Year Results of Continuous Treatment With Etanercept.

Rios Rodriguez V, Hermann KG, Weiß A, Listing J, Haibel H, Althoff C, Proft F, Behmer O, Sieper J, Poddubnyy D.

Arthritis Rheumatol. 2019 Jan 9. doi: 10.1002/art.40786. [Epub ahead of print]

PMID:
30625261
4.

The majority of patients with newly diagnosed juvenile idiopathic arthritis achieve a health-related quality of life that is similar to that of healthy peers: results of the German multicenter inception cohort (ICON).

Listing M, Mönkemöller K, Liedmann I, Niewerth M, Sengler C, Listing J, Foell D, Heiligenhaus A, Klein A, Horneff G, Ganser G, Haas JP, Klotsche J, Minden K.

Arthritis Res Ther. 2018 May 30;20(1):106. doi: 10.1186/s13075-018-1588-x.

5.

Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort.

Poddubnyy D, Listing J, Haibel H, Knüppel S, Rudwaleit M, Sieper J.

Rheumatology (Oxford). 2018 Apr 1;57(4):703-711. doi: 10.1093/rheumatology/kex475.

PMID:
29373733
6.

Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort.

Baganz L, Richter A, Kekow J, Bussmann A, Krause A, Stille C, Listing J, Zink A, Strangfeld A.

Rheumatol Int. 2018 Apr;38(4):579-587. doi: 10.1007/s00296-017-3870-7. Epub 2017 Nov 16.

7.

Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort.

Protopopov M, Sieper J, Haibel H, Listing J, Rudwaleit M, Poddubnyy D.

Arthritis Res Ther. 2017 Oct 24;19(1):240. doi: 10.1186/s13075-017-1453-3.

8.

Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project.

Mercer LK, Regierer AC, Mariette X, Dixon WG, Baecklund E, Hellgren K, Dreyer L, Hetland ML, Cordtz R, Hyrich K, Strangfeld A, Zink A, Canhao H, Hernandez MV, Tubach F, Gottenberg JE, Morel J, Zavada J, Iannone F, Askling J, Listing J.

Ann Rheum Dis. 2017 Dec;76(12):2025-2030. doi: 10.1136/annrheumdis-2017-211623. Epub 2017 Aug 19.

9.

Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial.

Hartl A, Sieper J, Syrbe U, Listing J, Hermann KG, Rudwaleit M, Poddubnyy D.

Arthritis Res Ther. 2017 Jun 15;19(1):140. doi: 10.1186/s13075-017-1350-9.

11.

Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort.

Meissner Y, Richter A, Manger B, Tony HP, Wilden E, Listing J, Zink A, Strangfeld A.

Ann Rheum Dis. 2017 Sep;76(9):1583-1590. doi: 10.1136/annrheumdis-2017-211209. Epub 2017 May 8.

12.

Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC.

Weiß A, Minden K, Listing J, Foeldvari I, Sieper J, Rudwaleit M.

RMD Open. 2017 Mar 21;3(1):e000366. doi: 10.1136/rmdopen-2016-000366. eCollection 2017.

13.

Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.

Poddubnyy D, Fedorova A, Listing J, Haibel H, Baraliakos X, Braun J, Sieper J.

J Rheumatol. 2016 Dec;43(12):2142-2148. Epub 2016 Nov 1.

PMID:
27803139
14.

Genomic stratification by expression of HLA-DRB4 alleles identifies differential innate and adaptive immune transcriptional patterns - A strategy to detect predictors of methotrexate response in early rheumatoid arthritis.

Stuhlmüller B, Mans K, Tandon N, Bonin MO, Smiljanovic B, Sörensen TA, Schendel P, Martus P, Listing J, Detert J, Backhaus M, Neumann T, Winchester RJ, Burmester GR, Häupl T.

Clin Immunol. 2016 Oct;171:50-61. doi: 10.1016/j.clim.2016.08.013. Epub 2016 Aug 26.

PMID:
27570220
15.

Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis.

Meissner Y, Zink A, Kekow J, Rockwitz K, Liebhaber A, Zinke S, Gerhold K, Richter A, Listing J, Strangfeld A.

Arthritis Res Ther. 2016 Aug 5;18(1):183. doi: 10.1186/s13075-016-1077-z.

16.

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.

Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, Aringer M, Meißner Y, Zink A, Listing J.

Ann Rheum Dis. 2017 Mar;76(3):504-510. doi: 10.1136/annrheumdis-2016-209773. Epub 2016 Jul 12.

17.

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.

Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, Strangfeld A, Zink A, Mariette X, Finckh A, Canhao H, Iannone F, Zavada J, Morel J, Gottenberg JE, Hyrich KL, Listing J.

Ann Rheum Dis. 2017 Feb;76(2):386-391. doi: 10.1136/annrheumdis-2016-209285. Epub 2016 Jun 15.

19.

Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force.

Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, Dasgupta B, Dixon WG, Geenen R, Huizinga TW, Kent A, de Thurah AL, Listing J, Mariette X, Ray DW, Scherer HU, Seror R, Spies CM, Tarp S, Wiek D, Winthrop KL, Buttgereit F.

Ann Rheum Dis. 2016 Jun;75(6):952-7. doi: 10.1136/annrheumdis-2015-208916. Epub 2016 Mar 1. Review.

PMID:
26933146
20.

Ankylosing spondylitis self-help organisations - do members differ from non-members?

Song IH, Brenneis C, Hammel L, Feldtkeller E, Listing J, Sieper J, Rudwaleit M.

Joint Bone Spine. 2016 May;83(3):295-300. doi: 10.1016/j.jbspin.2015.06.012. Epub 2015 Dec 8.

PMID:
26677993
21.

Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis.

Richter A, Listing J, Schneider M, Klopsch T, Kapelle A, Kaufmann J, Zink A, Strangfeld A.

Ann Rheum Dis. 2016 Sep;75(9):1667-73. doi: 10.1136/annrheumdis-2015-207838. Epub 2015 Nov 13.

22.

Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis--3-Year data of the ESTHER trial.

Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Weiß A, Freundlich B, Lange E, Rudwaleit M, Sieper J.

Semin Arthritis Rheum. 2016 Feb;45(4):404-10. doi: 10.1016/j.semarthrit.2015.08.005. Epub 2015 Sep 4.

PMID:
26519007
23.

Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS).

Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, Syrbe U, Braun J, Rudwaleit M.

Ann Rheum Dis. 2016 Aug;75(8):1438-43. doi: 10.1136/annrheumdis-2015-207897. Epub 2015 Aug 4.

PMID:
26242443
24.

Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.

Gerhold K, Richter A, Schneider M, Bergerhausen HJ, Demary W, Liebhaber A, Listing J, Zink A, Strangfeld A.

Rheumatology (Oxford). 2015 Oct;54(10):1858-66. doi: 10.1093/rheumatology/kev194. Epub 2015 May 21.

25.

The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers.

Kearsley-Fleet L, Závada J, Hetland ML, Nordström DC, Aaltonen KJ, Listing J, Zink A, Gati T, Rojkovich B, Iannone F, Gremese E, van Riel PLCM, van de Laar MAFJ, Lie E, Kvien TK, Canhão H, Fonseca JE, Rotar Ž, Loza E, Carmona L, Askling J, Johansson K, Finckh A, Dixon WG, Hyrich KL.

Rheumatology (Oxford). 2015 Jun;54(6):1074-1079. doi: 10.1093/rheumatology/keu446. Epub 2014 Nov 27.

PMID:
25433042
26.

Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial.

Detert J, Klaus P, Listing J, Höhne-Zimmer V, Braun T, Wassenberg S, Rau R, Buttgereit F, Burmester GR.

Trials. 2014 Oct 27;15:412. doi: 10.1186/1745-6215-15-412.

27.

Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial.

Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Weiß A, Lange E, Freundlich B, Rudwaleit M, Sieper J.

Rheumatology (Oxford). 2015 Feb;54(2):257-61. doi: 10.1093/rheumatology/keu263. Epub 2014 Aug 19.

PMID:
25140041
28.

Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial.

Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Weiß A, Buß B, Freundlich B, Lange E, Alten R, Rudwaleit M, Sieper J.

J Rheumatol. 2014 Oct;41(10):2034-40. doi: 10.3899/jrheum.140056. Epub 2014 Jul 15.

PMID:
25028375
29.

Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.

Callhoff J, Sieper J, Weiß A, Zink A, Listing J.

Ann Rheum Dis. 2015 Jun;74(6):1241-8. doi: 10.1136/annrheumdis-2014-205322. Epub 2014 Apr 9. Review.

PMID:
24718959
30.

Sustainability of rituximab therapy in different treatment strategies: results of a 3-year followup of a German biologics register.

Richter A, Strangfeld A, Herzer P, Wilden E, Bussmann A, Listing J, Zink A.

Arthritis Care Res (Hoboken). 2014 Nov;66(11):1627-33. doi: 10.1002/acr.22327.

32.

Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).

Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J.

Ann Rheum Dis. 2014 May;73(5):817-23. doi: 10.1136/annrheumdis-2013-204248. Epub 2014 Jan 3.

PMID:
24389297
33.

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab.

Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, Strangfeld A.

Ann Rheum Dis. 2015 Feb;74(2):415-21. doi: 10.1136/annrheumdis-2013-204021. Epub 2013 Nov 29.

34.

Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis.

Callhoff J, Weiß A, Zink A, Listing J.

Rheumatology (Oxford). 2013 Dec;52(12):2127-35. doi: 10.1093/rheumatology/ket266. Epub 2013 Aug 14. Review.

PMID:
23946435
35.

Vertebral erosions associated with spinal inflammation in patients with ankylosing spondylitis identified by magnetic resonance imaging: changes after 2 years of tumor necrosis factor inhibitor therapy.

Baraliakos X, Listing J, Haibel H, Sieper J, Braun J.

J Rheumatol. 2013 Nov;40(11):1891-6. doi: 10.3899/jrheum.120533. Epub 2013 Aug 1.

PMID:
23908444
36.

Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography.

Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, Van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Gaston H, Grunke M, Van Der Horst-Bruinsma IE, Landewé R, Leirisalo-Repo M, Sieper J, De Vlam K, Pappas D, Kiltz U, Van Der Heijde D, Braun J.

Ann Rheum Dis. 2014 Oct;73(10):1819-25. doi: 10.1136/annrheumdis-2013-203425. Epub 2013 Jul 14.

PMID:
23852807
37.

Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.

Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J.

Arthritis Res Ther. 2013;15(3):R67.

38.

Evaluation of the RABBIT Risk Score for serious infections.

Zink A, Manger B, Kaufmann J, Eisterhues C, Krause A, Listing J, Strangfeld A.

Ann Rheum Dis. 2014 Sep;73(9):1673-6. doi: 10.1136/annrheumdis-2013-203341. Epub 2013 Jun 5.

39.

Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare.

Haibel H, Heldmann F, Braun J, Listing J, Kupper H, Sieper J.

Arthritis Rheum. 2013 Aug;65(8):2211-3. doi: 10.1002/art.38014. No abstract available.

40.

Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial.

Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J.

Ann Rheum Dis. 2014 Jan;73(1):243-6. doi: 10.1136/annrheumdis-2012-203055. Epub 2013 Apr 26.

PMID:
23625982
41.

Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (GESPIC).

Poddubnyy D, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J, Rudwaleit M.

Ann Rheum Dis. 2013 Aug;72(8):1430-2. doi: 10.1136/annrheumdis-2012-203148. Epub 2013 Apr 26. No abstract available.

PMID:
23625981
42.

Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.

Baraliakos X, Haibel H, Listing J, Sieper J, Braun J.

Ann Rheum Dis. 2014 Apr;73(4):710-5. doi: 10.1136/annrheumdis-2012-202698. Epub 2013 Mar 16.

PMID:
23505240
43.

The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.

Listing J, Gerhold K, Zink A.

Rheumatology (Oxford). 2013 Jan;52(1):53-61. doi: 10.1093/rheumatology/kes305. Epub 2012 Nov 28. Review.

PMID:
23192911
44.

Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial.

Song IH, Weiß A, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Lange E, Freundlich B, Rudwaleit M, Sieper J.

Ann Rheum Dis. 2013 Jun;72(6):823-5. doi: 10.1136/annrheumdis-2012-202389. Epub 2012 Nov 21.

PMID:
23172749
45.

One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare.

Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Haug-Rost I, Braun J, Sieper J.

Ann Rheum Dis. 2013 Feb;72(2):305-6. doi: 10.1136/annrheumdis-2012-201926. Epub 2012 Aug 11. No abstract available.

PMID:
22887847
46.

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.

Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, Rockwitz K, Alten R, Krüger K, Rau R, Simon C, Gremmelsbacher E, Braun T, Marsmann B, Höhne-Zimmer V, Egerer K, Buttgereit F, Burmester GR.

Ann Rheum Dis. 2013 Jun;72(6):844-50. doi: 10.1136/annrheumdis-2012-201612. Epub 2012 Jun 27.

PMID:
22739990
47.

[Biomarkers in rheumatology. Biomarkers and imaging for the diagnosis and stratification of rheumatoid arthritis and spondylarthritis in the ArthroMark network funded by the Federal Ministry of Education and Research].

Häupl T, Appel H, Backhaus M, Burkhardt H, Grünke M, Grützkau A, Hoppe B, Listing J, Ostendorf B, Rudwaleit M, Sieper J, Skapenko A, Skriner K, Sörensen T, Stuhlmüller B, Zink A, Schulze-Koops H, Burmester GR.

Z Rheumatol. 2012 Jun;71(4):314-8. doi: 10.1007/s00393-011-0781-y. German.

PMID:
22546912
48.

Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort.

Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J.

Ann Rheum Dis. 2012 Oct;71(10):1616-22. doi: 10.1136/annrheumdis-2011-201252. Epub 2012 Mar 29.

PMID:
22459541
49.

Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial.

Song IH, Althoff CE, Haibel H, Hermann KG, Poddubnyy D, Listing J, Weiß A, Djacenko S, Burmester GR, Bohl-Bühler M, Freundlich B, Rudwaleit M, Sieper J.

Ann Rheum Dis. 2012 Jul;71(7):1212-5. doi: 10.1136/annrheumdis-2011-201010. Epub 2012 Mar 22.

PMID:
22440819
50.

High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis.

Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, Baraliakos X, Listing J, Rudwaleit M, Schett G, Sieper J.

Ann Rheum Dis. 2012 Apr;71(4):572-4. doi: 10.1136/annrheumdis-2011-200216. Epub 2011 Dec 20.

PMID:
22186710

Supplemental Content

Loading ...
Support Center